Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain...

Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000
Brain System to Treat Patients With Functional Brain Disorders

TEL AVIV, Israel, July 14 /PRNewswire-FirstCall/ -- Elbit Imaging Ltd.
(TASE: EMIT, Nasdaq: EMITF), announced today that, its subsidiary (in which
EI holds indirectly approximately 58.34%, InSightec Ltd., announced today
that a team at the University Children's Hospital Zurich has completed a
feasibility study testing the use of non-invasive transcranial MR-guided
focused ultrasound surgery (TcMRgFUS) for the treatment of neuropathic pain.
Ten adult patients diagnosed with chronic neuropathic pain successfully
underwent non-invasive deep brain ablation surgery (central lateral
thalamotomy) with transcranial TcMRgFUS and showed improvement in pain scores
and reduction of pain medication with no adverse effects at three months
follow-up. This is the first study in the world to test non-invasive
transcranial focused ultrasound as a treatment modality for functional brain
disorders.
"The Neuropathic pain study performed at Zurich demonstrated the
feasibility to treat these patients non-invasively without adverse events and
with very favorable preliminary efficacy" said Dr. Kobi Vortman, President
and CEO of InSightec.
"The results of this study set the ground for extensive brain study
addressing the areas of functional diseases like Parkinson and Epilepsy,
brain tumors and stroke. This technology has the potential to help
significant amount of patients while reducing trauma and morbidity. To
advance this study InSightec is collaborating with leading neurosurgery and
neurology institutes around the world."
Shimon Yitzhaki, Elbit Imaging's President and CEO, commented:
InSightec's outstanding breakthrough technology in the transcranial field
has without doubt placed InSightec on the map as being the world's leading
developer in the field of non-invasive treatment using MR-guided focused
ultrasound surgery (MRgFUS) with an impressive variety of applications and
markets
About ExAblate(R)
ExAblate is the first system to use the MR guided focused ultrasound
technology that combines MRI - to visualize the body anatomy, plan the
treatment and monitor treatment outcome in real time - and high intensity
focused ultrasound to target brain tissue non-invasively. MR thermometry
allows the physician to control and adjust the treatment in real time to
ensure that the targeted area is fully treated and surrounding tissue is
spared. The ExAblate 4000 is a platform for a variety of transcranial
indications, such as brain tumors, functional neurosurgery, stroke and
targeted drug delivery.
The ExAblate(R) 2000, based on the same technology, was approved by the
U.S. Food and Drug Administration in 2004 as a treatment for symptomatic
uterine fibroids. 5,000 women have been treated worldwide to date. ExAblate
2000 received the European CE Mark certification for pain palliation of bone
metastases in June 2007.
About InSightec
InSightec Ltd. is a privately held company owned by Elbit Imaging,
General Electric, MediTech Advisors, LLC and employees. It was founded in
1999 to develop the breakthrough MR guided Focused Ultrasound technology and
transform it into the next generation operating room. Headquartered near
Haifa, Israel, the company has over 160 employees and has invested more than
$150 million in research, development, and clinical investigations. Its U.S.
headquarters are located in Dallas, Texas. For more information, please go
to: http://www.insightec.com/
About Elbit Imaging Ltd.
The Activities of Elbit Imaging Ltd. are divided into the following
principal fields: (i) Shopping and Entertainment Centers - Initiation,
construction, operation, management and sale of shopping and entertainment
centers and other mixed-use real property projects, predominantly in the
retail sector, located in Central and Eastern Europe and in India; (ii)
Hotels - Hotel ownership, operation, management and sale, primarily in major
European cities; (iii) Image Guided Treatment - Investments in the research
and development, production and marketing of magnetic resonance imaging
guided focused ultrasound treatment equipment; (vi) Residential Projects -
Initiation, construction and sale of residential projects and other mixed-use
real projects, predominantly residential, located in Eastern Europe and in
India; and (v) Other Activities - (a) The distribution and marketing of
fashion apparel and accessories in Israel; (b) venture capital investments;
and (c) investments in hospitals, and farm and dairy plants in India, which
are in preliminary stages.
Any forward-looking statements in our releases include statements
regarding the intent, belief or current expectations of Elbit Imaging Ltd.
and our management about our business, financial condition, results of
operations, and its relationship with its employees and the condition of our
properties. Words such as "believe," "expect," "intend," "estimate" and
similar expressions are intended to identify forward-looking statements but
are not the exclusive means of identifying such statements. Actual results
may differ materially from those projected, expressed or implied in the
forward-looking statements as a result of various factors including, without
limitation, the factors set forth in our filings with the Securities and
Exchange Commission including, without limitation, Item 3.D of our annual
report on Form 20-F for the fiscal year ended December 31, 2008, under the
caption "Risk Factors." Any forward-looking statements contained in our
releases speak only as of the date of such release, and we caution existing
and prospective investors not to place undue reliance on such statements.
Such forward-looking statements do not purport to be predictions of future
events or circumstances, and therefore, there can be no assurance that any
forward-looking statement contained our releases will prove to be accurate.
We undertake no obligation to update or revise any forward-looking
statements. All subsequent written or oral forward-looking statements
attributable to us or persons acting on our behalf are expressly qualified in
their entirety by the cautionary statements set forth in our filings with the
Securities and Exchange Commission including, without limitation, Item 3.D of
our annual report on Form 20-F for the fiscal year ended December 31, 2008,
under the caption "Risk Factors."
For Further Information:

Company Contact:

Shimon Yitzhaki, President
Elbit Imaging Ltd.
Tel: +972-3-608-6000
syitzhaki@elbitimaging.com

Dudi Machluf, CFO
Elbit Imaging Ltd.
Tel: +972-3-608-6024
dudim@elbitimaging.com

Investor Contact:

Mor Dagan
Investor Relations
Tel: +972-3-516-7620
mor@km-ir.co.il

SOURCE Elbit Imaging Ltd.

Company Contact: Shimon Yitzhaki, President, Elbit Imaging Ltd., Tel:
+972-3-608-6000, syitzhaki@elbitimaging.com; Dudi Machluf, CFO, Elbit Imaging
Ltd., Tel: +972-3-608-6024, dudim@elbitimaging.com; Investor Contact: Mor
Dagan, Investor Relations, Tel: +972-3-516-7620, mor@km-ir.co.il